• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

风湿性多肌痛和巨细胞动脉炎患者血清中的白细胞介素-6

Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis.

作者信息

Dasgupta B, Panayi G S

机构信息

Rheumatology Unit, UMDS, Guy's Hospital, London.

出版信息

Br J Rheumatol. 1990 Dec;29(6):456-8. doi: 10.1093/rheumatology/29.6.456.

DOI:10.1093/rheumatology/29.6.456
PMID:2124160
Abstract

Polymyalgia rheumatica and giant cell arteritis are diseases which are characterized by a brisk acute phase response. Cytokines, principally interleukin-1 and interleukin-6, are thought to mediate the release of acute phase proteins from hepatocytes. Employing a sensitive bioassay based on the hybridoma growth factor properties of interleukin-6, we investigated its levels in sequential sera obtained from 15 initially untreated patients with PMR/GCA. We found that interleukin-6 activity was significantly elevated in all untreated patients. Although there was a significant decline in its levels after successful steroid therapy, seven patients continued to have raised serum levels of interleukin-6 for up to 6 months after initiation of treatment. Activated endothelial cells are a potent source of interleukin-6 and its persistence in the circulation may be taken as evidence of continuing disease activity. What is not explicable is the normalization of the acute phase response soon after the commencement of steroid therapy when circulating levels of interleukin-6 are still high. This suggests that steroids may be having additional effects on hepatocyte function.

摘要

风湿性多肌痛和巨细胞动脉炎是以急性期反应活跃为特征的疾病。细胞因子,主要是白细胞介素-1和白细胞介素-6,被认为介导了肝细胞释放急性期蛋白。我们采用基于白细胞介素-6杂交瘤生长因子特性的灵敏生物测定法,研究了15例未经治疗的PMR/GCA患者连续血清中白细胞介素-6的水平。我们发现,所有未经治疗的患者白细胞介素-6活性均显著升高。虽然成功使用类固醇治疗后其水平显著下降,但7例患者在开始治疗后长达6个月血清白细胞介素-6水平仍升高。活化的内皮细胞是白细胞介素-6的重要来源,其在循环中的持续存在可能被视为疾病持续活动的证据。无法解释的是,在类固醇治疗开始后不久急性期反应就恢复正常,而此时循环中的白细胞介素-6水平仍然很高。这表明类固醇可能对肝细胞功能有额外的作用。

相似文献

1
Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis.风湿性多肌痛和巨细胞动脉炎患者血清中的白细胞介素-6
Br J Rheumatol. 1990 Dec;29(6):456-8. doi: 10.1093/rheumatology/29.6.456.
2
Serum immunoglobulin G4 in giant cell arteritis and polymyalgia rheumatica.巨细胞动脉炎和风湿性多肌痛中的血清免疫球蛋白G4
Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):94-97. Epub 2016 Dec 2.
3
Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis.从风湿性多肌痛和巨细胞动脉炎患者外周血中选择性消耗和激活CD8 +淋巴细胞。
Ann Rheum Dis. 1989 Apr;48(4):307-11. doi: 10.1136/ard.48.4.307.
4
Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.风湿性多肌痛和巨细胞动脉炎中的循环T细胞亚群:泼尼松龙治疗后CD8 +细胞百分比的变化。
Ann Rheum Dis. 1993 Oct;52(10):730-3. doi: 10.1136/ard.52.10.730.
5
Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis.风湿性多肌痛和巨细胞动脉炎中白细胞介素-6产生与疾病活动的相关性。
Arthritis Rheum. 1993 Sep;36(9):1286-94. doi: 10.1002/art.1780360913.
6
Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.巨细胞动脉炎和风湿性多肌痛与疾病活动相关的血清标志物。
Rheumatology (Oxford). 2015 Aug;54(8):1397-402. doi: 10.1093/rheumatology/keu526. Epub 2015 Feb 26.
7
Lymphocyte subpopulations analysis in peripheral blood in polymyalgia rheumatica/giant cell arteritis.
Br J Rheumatol. 1993 Aug;32(8):666-70. doi: 10.1093/rheumatology/32.8.666.
8
Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis. Clinical and laboratory correlations.风湿性多肌痛/巨细胞动脉炎中的可溶性白细胞介素2受体。临床与实验室相关性。
J Rheumatol. 1992 Jul;19(7):1100-6.
9
Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis.白细胞介素-6在风湿性多肌痛和巨细胞动脉炎临床复发中的作用
Ann Rheum Dis. 1996 Jun;55(6):403-4. doi: 10.1136/ard.55.6.403-b.
10
Plasma adrenomedullin levels in patients with polymyalgia rheumatica and giant cell arteritis.风湿性多肌痛和巨细胞动脉炎患者的血浆肾上腺髓质素水平。
Clin Exp Rheumatol. 2006 Mar-Apr;24(2 Suppl 41):S6-9.

引用本文的文献

1
Trajectory analysis of glucocorticoid treatment highlights issues in the current tapering strategy for polymyalgia rheumatica.糖皮质激素治疗的轨迹分析凸显了目前风湿性多肌痛减药策略中存在的问题。
RMD Open. 2025 Jul 25;11(3):e005650. doi: 10.1136/rmdopen-2025-005650.
2
Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments.治疗巨细胞动脉炎的传统与新兴策略:新疗法洞察
J Clin Med. 2024 Oct 29;13(21):6492. doi: 10.3390/jcm13216492.
3
Anti-interleukin-6 receptor antibody for the treatment of remitting seronegative symmetrical synovitis with pitting oedema: a new outlook?
抗白细胞介素-6 受体抗体治疗缓解型血清阴性对称性滑膜炎伴凹陷性水肿:新视角?
BMJ Case Rep. 2024 Mar 15;17(3):e257645. doi: 10.1136/bcr-2023-257645.
4
Advances and challenges in management of large vessel vasculitis.大血管血管炎管理的进展与挑战
Rheumatol Immunol Res. 2023 Dec 19;4(4):188-195. doi: 10.2478/rir-2023-0028. eCollection 2023 Dec.
5
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.一项评估沙利鲁单抗治疗巨细胞动脉炎患者的疗效和安全性的 3 期随机、双盲、安慰剂对照研究。
Arthritis Res Ther. 2023 Oct 16;25(1):199. doi: 10.1186/s13075-023-03177-6.
6
Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?巨细胞动脉炎和风湿性多肌痛靶向治疗时代的生物标志物:是否有可能替代急性期反应物?
Front Immunol. 2023 Jun 15;14:1202160. doi: 10.3389/fimmu.2023.1202160. eCollection 2023.
7
Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review.托珠单抗治疗青少年特发性关节炎相关性葡萄膜炎:一篇叙述性综述
Children (Basel). 2023 Feb 23;10(3):434. doi: 10.3390/children10030434.
8
Predictors of complete 24-month remission and flare in patients with polymyalgia rheumatica.风湿性多肌痛患者24个月完全缓解和复发的预测因素。
Clin Exp Med. 2023 Nov;23(7):3391-3397. doi: 10.1007/s10238-022-00976-0. Epub 2022 Dec 24.
9
Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica.致炎辅助性 T 细胞 1 和 17 细胞在巨细胞动脉炎中的腱鞘炎和滑囊炎中的作用。
Front Immunol. 2022 Aug 11;13:943574. doi: 10.3389/fimmu.2022.943574. eCollection 2022.
10
Tocilizumab for giant cell arteritis.托珠单抗治疗巨细胞动脉炎。
Cochrane Database Syst Rev. 2022 May 13;5(5):CD013484. doi: 10.1002/14651858.CD013484.pub3.